Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Strategies for Prevention and Screening of CRM Conditions
Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.
EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
Now Viewing
EP: 2.Strategies for Prevention and Screening of CRM Conditions
EP: 3.The Link Between Obesity and CRM Conditions
EP: 4.Challenges in Managing Co-Morbid CRM Conditions
EP: 5.Contemporary Guidelines for CRM Conditions
EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions
EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM
EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines
EP: 10.Care Coordination for High-Risk CRM Patients
EP: 11.Takeaways from the UH CINEMA Program
EP: 12.Exploring the Kidney-CHAMP Study
EP: 13.Insights from the COORDINATE-Diabetes Trial
EP: 14.Coordinating Initiatives to Enhance CRM Care
EP: 15.Implementing CRM Learnings and Utilization of Telehealth
Video content above is prompted by the following:
- What does a successful CRM prevention or screening program look like in practice?
- Can early intervention in patients with HF or T2D prevent CKD or vice versa?
- How can early screening for CKD be improved and effectively implemented across different healthcare settings?
- What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
- How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
